光學分子影像：2010年

光學分子影像：2010年 是由出版商Strategies Unlimited在2010年01月所出版的。 這份英文市場調查報告書包含70 Pages 價格從美金4950起跳。

簡介

本報告，針對光學分子影像（OMI）市場的現狀與展望進行調查分析，並彙整OMI的應用別收益預測（∼2014年）、主要企業的OMI系統的銷售台數推算、技術以及應用的發展趨勢、主要系統供應商的市佔率、檔案資料等，由下列摘要形式闡述。

第1章 報告摘要

第2章 簡介

第3章 光學分子影像的定義

• 何謂體內光學分子影像
• 螢光
  • 基本硬體
  • 螢光分子
  • 課題
• 生物光（Bioluminescence）
  • 基本硬體
  • 冷光酵素
  • 課題
• OMI的影響的擴展
  • 多光譜影像與光譜分離
  • 螢光分子斷層掃描
  • 近紅外線螢光
  • 光線傳輸
  • 光學分子影像結合既有的影像系統
  • 新技術：光聲系統
  • 結論

第4章 光學分子影像的應用

• 前臨床應用
  • 藥物開發的小動物研究
  • 疾病觀察的小動物研究
• 臨床應用
  • 癌症手術
  • 乳癌診斷
  • 人體淋巴系統的繪圖
  • 臨床試驗

第5章 光學分子影像市場的市場預測

• 預測摘要
• OMI整體的市佔率
• 前臨床的機會
• 臨床的機會
• 關於顯像劑
• 預測影響因素
• 最終預測分析

第6章 主要企業・產品的檔案資料

• Advanced Research Technologies Inc.
• AntiCancer Inc.
• Caliper LifeSciences
• Cambridge Research and Instrumentation (CRi)
• Carestream Molecular Imaging
• Fluoptics
• GE Healthcare
• INDEC BioSystems, Inc.
• LI-COR Biosciences
• O2view
• Spectros Corporation
• VisEn Medical Inc.

目錄

Abstract

In vivo optical molecular imaging (OMI) is poised to move into clinical use as one of the key tools in personalized medicine, complementing more established imaging tools such as CT and MRI. Growth of equipment sales is on track to reach $400 million in 2014 and nearly $1 billion by the end of the decade. However, this strong growth hinges on partnerships with key medical equipment vendors, the outcomes of clinical trials assessing imaging agents, regulatory approvals, patent litigation, and decisions about insurance reimbursement. These are some of the findings in this new report, the first ever to cover this emerging technology.

Optical molecular imaging is an attractive and cost-effective tool for examining and monitoring disease states and to determine a drug' s effectiveness in living tissue. Highly portable, fast, and less expensive than conventional imaging technologies, it has the potential to bring sophisticated diagnostics right to the doctor' s office. When coupled with more traditional imaging tools such as CT and MRI, optical imaging adds an unprecedented degree of quantification and specificity to the healthcare decision-making process.

The market will likely expand in two complementary directions: research systems and clinical systems. The research market will continue at a steady pace as OMI approaches become more widely used for drug discovery and preclinical studies. Recent advances in imaging agents will power the transition of optical techniques from the lab to clinical settings. Cameras and optical filters will also be integral components of the clinical devices.

Large imaging firms, such as GE Healthcare, Siemens, and Philips, are beginning to pursue optical mo lecular imaging, while over 12 companies are already marketing OMI systems.

This new report - the first to cover this emerging segment of optical systems - discusses the market opportunities, technology trends, leading system vendors, and key factors that will influence the market as the optical technique is used more broadly. Strategies Unlimited has a reputation for providing deep and trustworthy reporting on complex markets. The report adds to the Strategies Unlimited portfolio of market reports on optical components and systems, including a related report on Optical Coherence Tomography (OCT), as well as reports on image sensors, laser applications, and lighting systems.

Table of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION

• 2.1 Methodology
• 2.2 Overview of the Optical Molecular Imaging Market

3. OPTICAL MOLECULAR IMAGING DEFINED

• 3.1 What is In Vivo Optical Molecular Imaging?
• 3.2 Fluorescence
  • 3.2.1 Basic Hardware
  • 3.2.2 Fluorescent Molecules
  • 3.2.3 Challenges
• 3.3 Bioluminescence
  • 3.3.1 Basic Hardware
  • 3.3.2 Luciferase Enzymes
  • 3.3.3 Challenges
• 3.4 Extending the Reach of OMI
  • 3.4.1 Multispectral Imaging and Spectral Unmixing
  • 3.4.2 Fluorescence Molecular Tomography
  • 3.4.3 Near-Infrared Fluorescence
  • 3.4.4 Light Delivery
  • 3.4.5 Optical Molecular Imaging Coupled with Existing Imaging Modalities
  • 3.4.6 Emerging Technologies: Photoacoustic Systems
  • 3.4.7 Conclusion

4. APPLICATIONS OF OPTICAL MOLECULAR IMAGING

• 4.1 Preclinical Applications
  • 4.1.1 Small Animal Studies for Drug Development
  • 4.1.2 Small Animal Studies for Disease Monitoring
• 4.2 Clinical Applications
  • 4.2.1 Oncology Surgery
  • 4.2.2 Breast Cancer Diagnosis
  • 4.2.3 Mapping the Human Lymphatic System
  • 4.2.4 Clinical Trials

5. OPTICAL MOLECULAR IMAGING MARKET FORECAST

• 5.1 Forecast Summary
• 5.2 Overall OMI Market Share
• 5.3 Preclinical Opportunities
• 5.4 Clinical Opportunities
  • 5.4.1 Hospital Settings - Oncology Surgery
  • 5.4.2 Doctors' Offices - Diagnostics and Therapy Monitoring
  • 5.4.3 Breast Cancer Imaging and Diagnosis
  • 5.4.4 Colorectal Cancer Diagnosis
• 5.5 A Word About Imaging Agents
• 5.6 Factors Influencing the Forecast
  • 5.6.1 FDA Approval
  • 5.6.2 Intellectual Property Rights
  • 5.6.3 Insurance Reimbursement
• 5.7 Final Forecast Thoughts

6. PROFILES OF LEADING COMPANIES AND PRODUCTS

• 6.1 Advanced Research Technologies Inc.
• 6.2 AntiCancer Inc.
• 6.3 Caliper LifeSciences
• 6.4 Cambridge Research and Instrumentation (CRi)
• 6.5 Carestream Molecular Imaging
• 6.6 Fluoptics
• 6.7 GE Healthcare
• 6.8 INDEC BioSystems, Inc.
• 6.9 LI-COR Biosciences
• 6.10 O2view
• 6.11 Spectros Corporation
• 6.12 VisEn Medical Inc.
• 6.13 Preclinical Imaging Systems and Agents
• 6.14 Timeline

LIST OF FIGURES

• 1.1 Overall OMI Revenue Market Share, 2009
• 1.2 OMI Revenue Forecast by Application, 2009-2014
• 2.1 Estimate of Unit Sales of OMI Systems by Company
• 3.1 Visible and Near-Infrared Wavelengths in the Spectrum
• 3.2 Fluorescent Probes
• 3.3 Commercial Setup for the IVIS Spectrum, a Combined Bioluminescence/ Fluorescence System
• 3.4 Simultaneous Quantification of Five Mixing Agents
• 3.5 Commercial Setup for Fluorescence Molecular Tomography
• 4.1 Comparing IVIS Imaging to Conventional Detection
• 4.2 Stages of the Drug Development Process
• 4.3 3D Image of a Lung Tumor Using Bioluminescence
• 4.4 ART' s SoftScan Optical Breast Imager
• 4.5 Imaging the Human Lymphatic System
• 5.1 OMI Revenue Forecast by Application, 2009-2014
• 5.2 Overall OMI Revenue Share, 2009
• 5.3 Preclinical Imaging System Revenue Share, 2009
• 5.4 New Companies Will Enter the Market by Mid-Decade
• 5.5 The Combination of OMI Agents and Imaging Systems Provides Many Options for Clinical Use
• 5.6 New Cancer Cases per Year through 2030
• 5.7 The SoftScan Breast Imager
• 5.8 The Imaging Agent Development Process
• 6.1 OMI Timeline

LIST OF TABLES

• 3.1 Wavelength and Associated Tissue Penetration
• 4.1 Selected Target Molecules and Their Related Disease Processes
• 4.2 Selected Clinical Trials
• 5.1 OMI Forecast by Application - Units, Prices, and Revenues, 2009-2014
• 5.2 Comparison of Cost per Scan and Insurance Reimbursement by Imaging Modality
• 6.1 Geographic Placement of OMI Companies
• 6.2 Preclinical Imaging Systems and Agents

相關商品

分子呈像/呈影劑相關市場調查報告書

顯影劑的全球市場
Imaging Agents
價格 : US $ 4500
出版日期 : 2012年02月

藥物發明，臨床診斷，分子影像的光學影像技術的新興趨勢
Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging
價格 : US $ 6500
出版日期 : 2011年10月

分子影像:時代的來到
Molecular Imaging: A market coming of age
價格 : US $ 1740
出版日期 : 2011年08月

Strategies Unlimited發行的醫療設備相關市場調查報告書

光干涉斷層計(2010年):技術˙應用˙市場

Optical Coherence Tomography 2010: Technology, Applications, and Market

價格 : US $ 4950

出版日期 : 2010年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!